MedTrace Logo

DAO DEFICIENCY SCREENING AMONG PATIENTS WITH INSOMNIA SYMPTOMS

NCT06488027 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-05-30

No results posted yet for this study

Summary

Insomnia is prevalent in the global population. Diamino oxidase (DAO) is an enzyme that degrades histamine. When there is not enough DAO enzyme activity in the body, histamine accumulates and it can lead to symptoms in the nervous system, among others. In this study we wanted to study the prevalence of DAO deficiency in pacients with insomnia symptoms.

Conditions

Sponsors & Collaborators

  • AB Biotek

    lead INDUSTRY

Principal Investigators

  • Julia Ferrer Garcia, MSc · AdSalutem Sleep Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-05
Primary Completion
2023-11-27
Completion
2023-11-27

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06488027 on ClinicalTrials.gov